Abstract
Tenecteplase, a genetically modified version of human tissue plasminogen activator (alteplase), is more selective than alteplase for the fibrin in blood clots and is more resistant to endogenous inactivation. Therefore, tenecteplase is administered as a single 5- to 10-second intravenous bolus, rather than the hour-long infusion that is required for alteplase. A previous dose-finding randomized trial of tenecteplase for stroke …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
